Clinical significance of CA19-9 in diagnosis of digestive tract tumors

Table 1 Serum CA19-9 concentration in patients and healthy controls

	n	-x ± s	Range	> 31.0 kU/L	PR, %
Gastric cancer
Preoperation	46	170.69 ± 91.45a	10.3-3220.0	19	41.3
Postoperative stability	15	12.62 ± 3.26	0.2-22.8	0	0.0
Postoperative recurrence	9	393.17 ± 3.804	9.0-2843.8	7	77.8
Colorectal cancer
Preoperation	50	152.69 ± 76.39a	0.2-3261.0	20	40.0
Postoperative stability	24	14.15 ± 2.25	0.0-31.0	0	0.0
Postoperative recurrence	16	87.21 ± 39.55a	0.5-657.8	11	68.7
Pancreatic cancer	7	1266.58 ± 521.31b	11.0-3220.0	6	83.3
Esophageal cancer	10	19.94 ± 6.31	0.0-53.0	2	20.0
Benign disorders	30	14.23 ± 2.60	0.0-27.2	0	0.0
Healthy controls	111	11.25 ± 0.57	0.0-27.5	0	0.0

^aP < 0.05 vs healthy controls;

^bP < 0.01 vs healthy controls. PR: Positive rate.

Table 2 Evaluational indexes for CA19-9-based diagnosis of gastrointestinal benign and malignant diseases

Disease	n	Positive	Se, %	Sp, %	Ac, %	+PV, %	-PV, %
Gastric cancer
Preoperation and recurrence	55	26	47.3	100.0	65.9	100.0	50.8
Colorectal cancer
Preoperation and recurrence	66	33	50.0	100.0	65.6	100.0	47.6
Esophageal cancer	10	2	20.0	100.0	80.0	100.0	78.9
Pancreatic cancer	7	6	83.3	100.0	97.3	100.0	96.8
GI benign disorders	30	0	0.0	100.0	78.7		787

Se, Sensitivity; Sp, Specificity; Ac, Accuracy; +PV, Positive predictive value; -PV, Negative predictive value.